Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Nadroparin calcium injection passed consistency evaluation.

Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that the company has recently received the approval notice from the National Medical Products Administration (NMPA) for the supplementary application of Nadroparin Calcium Injection 0.3ml: 3075AaIU and 0.6ml: 6150AaIU. This product has been approved through the generic drug quality and efficacy consistency evaluation. Nadroparin Calcium Injection is used in surgical procedures to prevent venous thromboembolic diseases in situations of moderate to high risk of venous thrombosis. It is also used to treat established deep vein thrombosis and in combination with aspirin for the treatment of unstable angina and acute phase of non-Q-wave myocardial infarction. It is also used in blood dialysis to prevent blood clot formation in extracorporeal circulation.